 And there's all these other hurdles that you have to go through and financial costs to get approval in market and post-market evaluation and monitoring of a drug versus a device used as an agent. And they argued the FDA can't randomly call a device a drug. And the FDA said, oh, yeah, because essentially when we rewrote the guidance, we're saying all devices are drugs.